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Introduction
The connection between epithelial mesenchymal transition 
(EMT) and cancer progression has been implicated in 
several types of cancer, including breast, prostate, pan-
creatic, and liver cancers [1–3]. Indeed, mounting evidence 
suggests that co- opting of EMT, an evolutionarily conserved 
process required for tissue morphogenesis during embry-
onic development, plays a critical role in tumor invasion, 
acquisition of cancer stem cell- like properties, and the 
development of metastasis and drug resistance [4]. While 
loss of E- cadherin expression represents a primal event 
in EMT, we increasingly appreciate that EMT is a complex 
process that is orchestrated by activation and repression 
of a growing and still incomplete list of genes, proteins, 
and transcriptional factors including ZEB1, SNAIL, TWIST, 
CDH2, and VIM among others [5–7]. Although several 
different EMT- related gene expression signatures (GES) 
have been reported to date attempting to capture key 
EMT- associated genes and regulators of EMT, they have 
been limited in part by variations observed between cell 
lines, limited concordance between different EMT induc-
tion models, and lack of functional validation [8–12]. 
Therefore, additional studies are still needed to identify 
both a robust, common set of EMT- associated genes and 
regulators in order to help improve our understanding 
ORIGINAL RESEARCH
Transcriptome profiling reveals novel gene expression 
signatures and regulating transcription factors of  
TGFβ- induced epithelial- to- mesenchymal transition
Liutao Du1, Shota Yamamoto1, Barry L. Burnette1, Danshang Huang1, Kun Gao2,  
Neema Jamshidi1 & Michael D. Kuo1,3
1Department of Radiology, The David Geffen School of Medicine at UCLA, Los Angeles, California 90095
2Department of Neurology, UCLA, Los Angeles, California 90095
3Department of Bioengineering, University of California-Los Angeles, Los Angeles, California 90095
© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, 
distribution and reproduction in any medium, provided the original work is properly cited.
Keywords
Breast, epithelial to mesenchymal transition, 
genomics, transcription factor, non-small-cell 
lung cancer
Correspondence
Michael D. Kuo, Department of Radiology, 
University of California-Los Angeles, David 
Geffen School of Medicine, Los Angeles, CA. 
Tel: (310) 825 1034; Fax: (310) 825 1034;  
E-mail: mikedkuo@gmail.com
Received: 30 November 2015; Revised: 4 
February 2016; Accepted: 20 February 2016
Cancer Medicine 2016; 5(8):1962–1972
doi: 10.1002/cam4.719
Abstract
Dysregulated epithelial to mesenchymal transition (EMT) in cancer cells endows 
invasive and metastatic properties upon cancer cells that favor successful colo-
nization of distal target organs and therefore play a critical role in transforming 
early- stage carcinomas into invasive malignancies. EMT has also been associated 
with tumor recurrence and drug resistance and cancer stem cell initiation. 
Therefore, better understanding of the mechanisms behind EMT could ultimately 
contribute to the development of novel prognostic approaches and individual-
ized therapies that specifically target EMT processes. As an effort to characterize 
the central transcriptome changes during EMT, we have developed a Transform-
ing growth factor (TGF)-beta- based in vitro EMT model and used it to profile 
EMT- related gene transcriptional changes in two different cell lines, a non-small 
cell lung cancer cell line H358, and a breast cell line MCF10a. After 7 days of 
TGF- beta/Oncostatin M (OSM) treatment, changes in cell morphology to a 
mesenchymal phenotype were observed as well as concordant EMT- associated 
changes in mRNA and protein expression. Further, increased motility was noted 
and flow cytometry confirmed enrichment in cancer stem cell- like populations. 
Microarray- based differential expression analysis identified an EMT- associated 
gene expression signature which was confirmed by RT- qPCR and which sig-
nificantly overlapped with a previously published EMT core signature. Finally, 
two novel EMT- regulating transcription factors, IRF5 and LMCD1, were identi-
fied and independently validated.
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of EMT, which could serve to drive future prognostic 
approaches and individualized therapies.
Here, we have developed a non- cell autonomous TGF- 
beta- based EMT induction model to profile and characterize 
the transcriptomic changes involved in the EMT process. 
After validation of our EMT induction model, we per-
formed gene expression microarray analysis and identified 
a common set of EMT- related genes in two different cell 
lines which shows strong concordance with a previously 
reported EMT- GES. Finally, we report on two new EMT- 
regulating transcription factors (TFs) that have potential 
direct regulation of this unique process.
Materials and Methods
Cell culture and EMT induction
H358, MCF10a, and A549 cells used in this study were 
purchased from the American Type Culture Collection 
(ATCC) and grown as per ATCC protocols and cultured 
in an incubator at 37°C in the presence 5% CO2. For 
the EMT induction, untreated cells (preEMT) were treated 
with a combination of TGF- beta (10 ng/mL) and OSM 
(50 ng/mL) for 7 days (postEMT) and then subsequently 
analyzed for EMT induction. Cell medium was changed 
every 3 days and fresh TGF- beta and OSM were added 
with each medium change. TGF- beta and OSM were 
purchased from Cell Signaling Technology (Danvers, MA).
Microarray and IPA pathway analysis
All RNA samples for expression analysis were isolated using 
RNAeasy kit (Qiagen, Valencia, CA) and inspected for 
quality using an Agilent 2100 Bioanalyzer (Agilent, Santa 
Clara, CA) and gel electrophoresis in the University of 
California Los Angeles (UCLA) Clinical Microarray Core 
(UCMC). All the RNAs were confirmed to be high quality 
with RIN scores over 8. Gene expression profiling was 
performed using Agilent 8 × 60 k arrays (Agilent, Santa 
Clara, CA). The microarray data was processed with the 
edgeR package to analyze differential expression of genes 
[13]. Ingenuity pathway analysis (IPA) software (Qiagen, 
Redwood City, CA) was used for analysis of the signaling 
and metabolic pathways, molecular networks, and biological 
processes most significantly perturbed in the gene expres-
sion datasets [14]. IPA was also used to predict TFs, which 
could be responsible for gene expression changes and 
whether those TFs are activated or inhibited in EMT.
RT- qPCR and EMT- gene- qPCR array
Total RNA was extracted using RNAeasy kit (Qiagen, 
Valencia, CA). Reverse- transcription reactions were 
catalyzed by Superscript III reverse transcriptase 
(Invitrogen, Carlsbad, CA). Subsequently, qPCR was per-
formed using SensiFAST SYBR Lo- ROX Kit (Bioland 
Scientific, Paramount, CA) on an ABI Fast 7500 Real- Time 
PCR System (Life Technologies, Grand Island, NY). All 
the qPCR primers were designed and validated by standard 
curve approaches. Relative quantification values were cal-
culated using the ddCt method after confirmation of 
equivalent amplification efficiencies between target genes 
and the reference gene. The EMT- gene qPCR array was 
purchased from Invitrogen (Life Technologies, Grand 
Island, NY). For all qPCR, two- step PCR cycling condi-
tion was used: 95°C for 2 min followed by 40 cycles of 
95°C for 5 sec, 60°C for 20 sec. Primer sequences are 
available upon request.
siRNA knockdown and western blots
Cells were treated with siRNA against each individual gene 
at concentrations described per Lipofectamine® RNAiMAX 
protocol (Invitrogen, Carlsbad, CA). The sequences of the 
two IRF5 siRNAs used were previously published (Catalog 
#16708; Ambion, Austin, TX) and were purchased from 
Invitrogen (Life Technologies, Grand Island, NY) [15]. 
The predesigned triple siRNAs to LMCD1 were ordered 
from Integrated DNA Technologies Inc (Coralville, Iowa) 
and #1 and #2 were validated and used in experiments. 
For western blotting, cells were collected and whole cell 
lysate was prepared with RIPA buffer and used for target 
protein analysis. All antibodies were purchased from 
Cell Signaling (Danvers, MA) and were used for over-
night incubation at 4°C according to manufacturers’ 
instructions.
Flow cytometry analysis
Cells were suspended in phosphate-buffered saline (PBS) 
with 20% fetal bovine serum (FBS) and incubated with 
relevant antibodies for 1 h on ice. Cells were then washed 
and resuspended with PBS + FBS for flow cytometry analysis 
(FACS) analysis on FACScanX (BD Biosciences, San Jose, 
CA) at the UCLA Flow Cytometry Core Laboratory. 
Antibodies against CD44 (PE- conjugated) and CD24 (APC- 
conjugated) were purchased from BD Biosciences (San 
Jose, CA); antibody against CD133 (PE- conjugated) was 
purchased from Miltenyi Biotec, (Cologne, Germany); 
antibody against E- cadherin (APC- conjugated) was pur-
chased from Biolegend (San Diego, CA).
Cell invasion assay
Cell invasion was measured by CytoSelect™ 24- Well Cell 
Migration and Invasion Assay (Cell Biolabs, San Diego, 
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CA) according to the manufacturer’s instructions. Briefly, 
the basement membrane layer of the cell culture inserts 
was rehydrated with serum- free media for 1 h. Media 
(10% FBS, 500 μL) was added to the lower well of the 
migration plate. Cells were prepared and suspended in 
serum- free media and were added to the inside of each 
insert and incubated for 48 h in an incubator. The 
media was aspirated from the inside of the insert, and 
nonmigratory cells were then removed. The insert was 
transferred to a clean well containing 400 μL of cell 
stain solution and incubated for 10 min and washed. 
Each insert was then transferred to an empty well and 
extraction solution was added at 200 μL per well, and 
then incubated for 10 min in an orbital shaker. From 
each sample, 100 μL was transferred to a 96- well 
 microtiter plate and measured for OD560 nm (BioTek, 
Winooski, VT).
Results
Identification of an EMT- related gene 
expression signature by microarray analysis
We optimized a TGF- beta- based EMT induction approach 
for use as an efficient and reproducible means of induc-
ing EMT in different cell lines (H358 and MCF10a). A 
7- day treatment of TGF- beta/OSM improved the efficiency 
of EMT induction, as compared to a single TGF- beta or 
OSM treatment, as demonstrated by protein expression 
changes of important EMT markers including E- cadherin, 
Vimentin, and Fibronectin (Fig. 1A; left panel: H358; right 
panel: MCF10a). TGF- beta/OSM was also more efficient 
for inducing EMT than other known EMT- inducing 
cytokines, such as HGF, FGF, and IGF (data not shown). 
In the H358 cells treated with TGF- beta/OSM, expression 
Figure 1. An optimized TGF- beta/OSM approach to efficiently induce epithelial mesenchymal transition (EMT) in H358 and MCF10a cells. (A) Western 
Blot of EMT protein for H358 cells (left) and for MCF10a cells (right). After 7 days of exposure to TGF- beta/OSM, a clear loss of epithelial biomarker 
E- cadherin and increased expression of mesenchymal proteins vimentin and N- cadherin are shown; (B) RT- qPCR quantification of 12 important EMT 
genes in H358 cells treated with TGF- beta/OSM; (C) TGF- beta/OSM- induced CSC- like cells: CD44+/CD24− subpopulation in H358 cells and CD133+ 
subpopulation in MCF10a cells. (D) Mesenchymal morphological changes; (E) cell invasiveness. *P < 0.05.
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of important EMT genes, such as CDH2, COL1A2, FN1, 
SNAI1, SNAI2, VIM, CDH1, and ERBB3, were all changed 
as expected after EMT induction (Fig. 1B). TGF- beta/
OSM also significantly increased the CSC- like subpopula-
tion cells in both cell lines (CD44+/CD24− or CD44+ in 
H358; CD133+ in MCF10a, Fig. 1C), induced mesenchymal 
morphological changes (Fig. 1D) and promoted cell inva-
siveness (Fig. 1E), which are consistent with previous 
reports.
To evaluate the transcriptomic changes during EMT in 
H358 and MCF10a cells, we used three independent sets 
of preEMT and postEMT RNA as biological triplicates 
for each cell line which were used for microarray- based 
gene expression profiling. We identified >2000 genes asso-
ciated with EMT (fold change >2, and P < 0.05). The 
top 50 significantly differentially expressed genes were 
listed in Table S1, all with fold change >16. A common 
GES of differentially expressed genes shared between the 
two cell lines consisting of 571 genes, with 269 genes 
upregulated and 302 genes downregulated (fold change 
>2, and P < 0.05) was identified (Table S2). Among these 
genes, ~127 genes had fold change >4 in both cell lines. 
The top- 10 upregulated common genes are SERPINB3, 
SERPINB4, SCG5, FAP, MMP9, GPR68, SERPINE1,CXCR7, 
ADAM19, and SLAMF8; the top- 10 downregulated com-
mon genes are KRT15 PSCA, FGFBP1, FXYD3, MAL2, 
GPR110, C10orf116, S100P, SUSD2, and MYO5C. After 
comparing our 571- EMT- GES with a previously published 
246- gene EMT- core- GES in breast cancer cells, we found 
58 overlapping genes (=5 × 10−42, hypergeometric distri-
bution) (Table S3), suggesting that these genes are a part 
of a core set of EMT- genes that are neither tissue or cell 
type specific [8].
Targeted validation of EMT transcriptomic 
profiles with RT- qPCR
To confirm the accuracy of our EMT gene expression 
signature, we selected 25 genes from the top 50 upregu-
lated and downregulated genes from our EMT GES and 
conducted RT- qPCR using newly prepared samples. The 
differential expression of all of these selected genes was 
successfully confirmed by RT- qPCR in this independent 
data set (Fig. 2). To further validate our microarray data 
results, we evaluated the mRNA levels of 65 genes that 
were previously reported to be related to EMT using a 
Figure 2. RT- qPCR confirmation of the differential expression of selected top genes in H358 and MCF10a cells. Cells were induced with TGF- 
beta/OSM for 7 days and RNAs were prepared. The top genes differentially expressed were selected in each cell line and validated by RT- qPCR to 
confirm their expression differences (GADPH was used as reference control). (A) Expression confirmation of selected genes in H358 cells; (B) Expression 
confirmation of selected genes in MCF10a cells. All tested genes were significantly differentially expressed after epithelial mesenchymal transition- 
induction (P < 0.05).
1966 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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commercial RT- qPCR array and compared with our micro-
array data results. The expression changes for 62 out of 
65 genes were validated (Table S4). The three genes that 
were not confirmed by the RT- qPCR EMT array had 
relatively low expression changes close to the cut- off ratio 
which was set at a fold change of 2. Together, these 
results confirm the reproducibility of our EMT- GES in 
independent samples.
EMT- related TFs and signaling networks 
identified in the EMT- GES
From our 571- EMT- GES, we found 34 TFs significantly 
differentially expressed during EMT induction (Table 1). 
The important known EMT- activating TFs, such as ZEB1, 
ZEB2, SNAIL1, SNAIL2, RUNX2, and ETS1, were all found 
upregulated, while known negative TF regulators of EMT, 
such as SMAD3, MITF, and ETF, were all downregulated 
in postEMT cells in concordance with the literature [16, 
17]. IPA also identified a number of TFs that did not 
show significant differential expression changes in postEMT 
cells but were predicted to be activated or inhibited based 
on the expression profiles of their target genes. For exam-
ple, TWIST1, TWIST2, HDAC6, MUC1, ETS2, NFkB, Jun, 
SP1, and AP1 were previously reported as enhancers of 
EMT, and were found activated in postEMT cells. Other 
TFs, such as ER, SPDEF, and HMGA1, were previously 
reported as repressors of EMT, and were found repressed 
in this study [18–20]. Interestingly, SMAD7 was previously 
reported as an EMT repressor; we found that SMAD7 
gene expression was consistently elevated after EMT induc-
tion and positively correlated with postEMT [21]. IPA 
Table 1. TFs that expressed differently in both H358 and MCF10a cells.
Gene Genbank ID Log2FC in H358 P- value in H358 Log2FC in 
MCF10a
P- value in 
MCF10a
Averaged log2FC
ZEB1 NM_001128128 3.42 7.67E- 06 1.64 1.22E- 02 2.53
SNAI1 NM_005985 3.17 2.55E- 05 4.1 7.50E- 05 3.64
SNAI2 NM_003068 2.6 7.61E- 03 2.21 1.21E- 02 2.41
MAF NM_001031804 2.48 6.02E- 04 1.63 6.16E- 04 2.06
ZEB2 NM_014795 2.42 5.76E- 04 1.3 7.03E- 03 1.86
ELK3 NM_005230 1.92 1.25E- 03 1.25 1.50E- 03 1.59
E2F7 NM_203394 1.9 1.54E- 02 1.04 6.46E- 03 1.47
SMAD7 NM_005904 1.86 3.15E- 03 2.47 1.02E- 03 2.17
ETS1 NM_005238 1.85 1.49E- 02 1.42 1.97E- 03 1.63
SMARCA1 NM_003069 1.77 1.29E- 03 1.2 2.00E- 02 1.49
RAI14 NM_015577 1.71 6.66E- 03 1.74 1.93E- 04 1.72
TGFB1I1 NM_001042454 1.63 1.88E- 03 2.12 2.03E- 03 1.88
LMCD1 NM_014583 1.58 1.34E- 02 4.5 8.46E- 05 3.04
SKIL NM_005414 1.56 1.20E- 04 2.34 1.66E- 03 1.95
JARID2 NM_004973 1.44 5.30E- 03 1.34 1.32E- 02 1.39
RUNX2 NM_004348 1.3 2.35E- 02 3.57 7.23E- 04 2.44
JAZF1 NM_175061 1.23 7.60E- 03 1.24 1.57E- 03 1.23
ID2 NM_002166 1.22 3.97E- 02 1.5 4.24E- 02 1.36
RNF2 NM_007212 1.11 5.58E- 03 1.31 1.58E- 02 1.21
MITF NM_198159 −1 4.39E- 02 −1.04 2.29E- 02 −1.02
NFIB NM_005596 −1 1.74E- 02 −2.88 2.18E- 04 −1.94
ZNF488 NM_153034 −1.02 8.26E- 03 −1.19 3.94E- 02 −1.11
EIF1AX NM_001412 −1.03 1.54E- 02 −1.05 3.77E- 03 −1.04
PIR NM_003662 −1.19 3.37E- 02 −1.39 3.72E- 03 −1.29
EEF1A2 NM_001958 −1.39 1.06E- 02 −1.03 2.99E- 02 −1.21
TBL1X NM_005647 −1.4 2.93E- 03 −1.25 7.93E- 03 −1.32
ELL3 NM_025165 −1.42 1.94E- 02 −2.41 8.62E- 05 −1.92
IKZF2 NM_001079526 −1.86 1.28E- 03 −1.48 8.96E- 03 −1.67
TOB1 NM_005749 −1.88 1.76E- 03 −1.72 6.52E- 03 −1.8
LSR NM_205834 −1.93 1.94E- 04 −1.76 7.17E- 03 −1.85
SMAD3 NM_005902 −1.94 1.06E- 03 −1.27 3.96E- 03 −1.61
IRF5 NM_001098627 −2.37 7.92E- 04 −1.33 9.89E- 04 −1.85
E2F2 NM_004091 −2.71 1.80E- 02 −2.62 9.89E- 05 −2.66
OVOL2 NM_021220 −3.53 2.66E- 05 −1.27 8.67E- 03 −2.4
EHF NM_012153 −4.26 2.49E- 06 −1.85 8.14E- 03 −3.05
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analysis also revealed that more than 10 networks (Nt) 
were activated during EMT; the top five common networks 
were shown in Fig. S1.
Novel EMT- regulating TFs identified and 
validated by functional studies
As shown in Table 1, certain TFs were found to be dif-
ferentially expressed after EMT induction, however, their 
roles in EMT have not been previously reported. We focused 
on two TFs that may be involved in EMT regulation: IRF5 
and LMCD1. IRF5′s expression was significantly inhibited 
after EMT, whereas LMCD1′s was significantly enhanced 
(Table 1). We first confirmed that IRF5 gene expression 
levels started to gradually decrease after EMT was induced 
by TGF- beta/OSM treatment, and then began to revert upon 
removal of the TGF- beta/OSM stimulus. Conversely, LMCD1 
gene expression levels increased after EMT was induced, 
and then decreased after the EMT process was reversed 
(Figs. 3A and B). To study their potential roles in EMT 
regulation, we used gene- specific siRNAs to knockdown each 
of these individual TFs in H358 cells, and then exposed 
the siRNA- treated cells to TGF- beta/OSM to examine if the 
TGF- beta- mediated EMT was subsequently hindered or 
enhanced. To validate the siRNA knockdown, two different 
siRNAs were optimized and knockdown efficiency for each 
siRNA confirmed by RT- qPCR (Fig. 3C). We found that 
inhibition of IRF5- enhanced TGF- beta mediated EMT pro-
gression, while conversely, knockdown of LMCD1 repressed 
TGF- beta- mediated EMT induction, as evidenced by the 
expression pattern of EMT protein biomarkers (Fig. 4A). 
FACS analysis of cell surface E- cadherin also indicated that 
knockdown of LMCD1 significantly reduced the E- cadherin- 
low- expressing cell subpopulation (from 9.8% to 4.2% (siR#1) 
or to 6% (siR#2), P < 0.05), while knockdown of IRF5 
increased the E- cadherin- low- expressing cell subpopulation 
(from 9.8% to 13.9% (siR#1), or to 12.3% (siR#2), P < 0.05) 
(Fig. 4B). Knockdown of LMCD1 also significantly reduced 
cell invasiveness of TGF- beta/OSM- treated cells (P < 0.05) 
(Fig. 4C), but no significant effect was seen on the CD24+ 
or CD44+ cell subpopulations (Fig. 4D), as compared to 
the scrambled control- siRNA- treated cells. Conversely, 
Figure 3. Time course of gene expression patterns of IRF5 and LMCD1 after 7 days of mesenchymal transition (EMT) induction with TGF- beta/OSM 
followed by removal of TGF- beta/OSM for 14 days and validation of siRNA- mediated knockdown efficiency of IRF5 and LMCD1 in H358 and MCF10a 
cells. (A) The relative expression levels of IRF5 and LMCD1 were measured by RT- qPCR in H358 and (B) MCF10a cells over a 21 days EMT induction- 
reversion time course in which the preEMT cells were first induced to undergo EMT via TGF- beta/OSM- based induction followed by removal of TGF- 
beta/OSM at day 7 (*P < 0.05; **P < 0.001, as compared to preEMT cells). (C) Confirmation of knockdown efficiency of selected siRNAs on LMCD 
and IRF5 gene expression in H358 cells; two siRNAs were optimized and used to knockdown their relative genes at 4 nmol/L (**P < 0.001, as 
compared to scramble- siR control).
1968 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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knockdown of IFR5 significantly promoted cell invasiveness 
of TGF- beta/OSM- treated cells (Fig. 4C), and dramatically 
increased the CD24+ subpopulation (from 0.4% to 35%, 
P < 0.001) and also increased the CD44+ subpopulation 
(from 6.2% to 14.9%, P < 0.05) (Fig. 4D), indicating its 
role in negative regulation of both CD24- and CD44- 
expressing cell populations during EMT. Further, cells treated 
with siR- IRF5 also showed a more EMT mesenchymal pat-
tern compared with control cells after EMT induction, while 
cells treated with siR- LMCD1 had slightly reduced, but 
recognizable EMT morphologic features (Fig. S2, in both 
H358 and MCF10a).
To investigate whether these effects observed in H358 
cells were cell type- dependent or not, we additionally 
conducted siRNA knockdown in breast MCF10a cells and 
a second lung cancer line, A549, that were both induced 
to undergo EMT by the same TGF- beta/OSM approach. 
Again, similar effects were observed in both cell lines. 
We also observed similar findings between MCF10a and 
H358 cells after knockdown of these two TFs; knockdown 
of IRF5 enhanced the EMT processes, while knockdown 
of LMCD1 inhibited EMT. These are indicated by the 
changes of critical EMT protein expression patterns 
(Fig. 5A), the E- cadherin- low- expressing cell subpopulation 
Figure 4. Effects of siRNA- mediated knockdown of IRF5 and LMCD1 on TGF- beta/OSM- induced epithelial mesenchymal transition (EMT) in H358 
cells. H358 cells were treated with each indicated siRNA (6 nmol/L) for 48 h and followed by induction of EMT using TGF- beta/OSM for 3 days. Cells 
were then collected for follow- up analysis. (A) Effects of siRNAs on EMT protein markers; (B) Effects of siRNAs on E- cadherin low- expressing 
subpopulation (labeled with anti- E- cadherin- APC antibody); (C) Effects of siRNAs on TGF- beta/OSM- mediated invasiveness; (D) Effects of siRNAs on 
CD24− and CD44+ subpopulations (labeled with CD24- PE and CD44- APC antibodies). Note: *P < 0.05; **P < 0.001, as compared to the postEMT 
scramble- siR control.
A
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(Fig. 5B), CD133+ subpopulation (Fig. 5C), and changes 
in invasion (Fig. 5D). Similar effects were also observed 
on E- cadherin- low cell population in A549 cells (Fig. 5E). 
Taken together, these data suggested that in a TGF- 
beta- mediated model of EMT, IRF5 may act as an impor-
tant EMT repressor while LMCD1 may act as an EMT 
enhancer. IRF5 may also play important roles in negative 
regulation of CD24 and CD44 subpopulations during EMT.
Discussion
EMT is believed to play a critical role in the cellular trans-
formation to an invasive and ultimately metastatic cancer 
phenotype. However, a detailed understanding of the genes 
involved and their regulation is incompletely understood. 
Herein, we present an efficient model of EMT induction 
with TGF- beta/OSM in MCF10a and H358 cell lines. We 
show that this model faithfully recapitulates characteristics 
associated with EMT including appropriate changes in 
mRNA and protein expression of key EMT- associated mark-
ers as confirmed by both PCR and western analysis, changes 
in cell morphology, changes in distribution of CSC- cell 
populations, and alterations in cell motility. Using this 
model, we then characterized gene expression patterns 
involved with EMT transduction in both a cancerous and 
noncancerous cell line from two different tissue sites and 
define a shared EMT- associated GES from which we then 
independently validated the top differentially expressed genes 
by RT- qPCR. The strong overlap between the 58 genes 
identified from our EMT GES with a published core EMT 
GES suggest that these 58 genes may be part of a larger 
core set of EMT- genes that are neither tissue or cell type 
specific [8]. Further studies will be required to confirm 
this, but these results are nonetheless intriguing.
Figure 5. Effects of siRNA- mediated knockdown of IRF5 and LMCD1 on TGF- beta/OSM- induced epithelial mesenchymal transition (EMT) in MCF10a 
and A549 cells. Cells were treated with each siRNA for 48 h at indicated concentrations followed by induction of EMT using TGF- beta/OSM for 3 days. 
Cells were then collected for follow- up analysis. (A) Effects on EMT protein markers in MCF10a cells (4 nmol/L of siRNA); (B) Effects on E- cadherin- 
low- expressing subpopulation in MCF10a cells, (4 nmol/L of siRNA); (C) Effects of siRNAs on CD133+ cell subpopulations (4 nmol/L of siRNA); (D) 
effects on invasion; and (E) Effects on E- cadherin- low- expressing subpopulation in A549 cells (4 nmol/L and 6 nmol/L for each siRNA). Note: *P < 0.05; 
**P < 0.001, as compared to the postEMT scramble- siR control.
A
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Interestingly, we found more than 10 networks activated 
during EMT. Nt 1 was centered on TGF- beta and involves 
nuclear proteins such as nup210, lipolysis- stimulated lipo-
protein receptor (LSR), V-Maf avian musculoaponeurotic 
fibrosarcoma oncogene homolog (MAF) and FILIp1L (Fig. 
S1). These proteins have been related to EMT regulation 
and cellular differentiation [22–25]. Nt2 was centered on 
NFkB and involved genes such as NFkB early- response gene 
IER3, secreted signaling molecules bone morphogenetic pro-
tein (BMP), and TF ETS homologous factor (EHT) that 
belongs to an ETS TF subfamily characterized by epithelial- 
specific expression and which may be involved in epithelial 
differentiation and carcinogenesis [26–29]. Nt3 was closely 
related to cancer and cellular movement being involved with 
the WNT pathway and ‘cadherin switch’ (repression of 
E- cadherin and expression of N- cadherin). Nt4 is related to 
cellular assembly and organization with vimentin and cytoker-
atin, and Nt5 involved signaling of cellular movement, cell- 
to- cell signaling, and interaction pathways regulated by SNAI1, 
SNAI2 and ZEB1, TGF- beta, WNT and BMP signaling 
pathways, which are believed to regulate embryonic stem 
cell progression. These data further substantiate the potential 
role these genes may have in EMT and CSC regulation [30].
Most interestingly, we identified two new TFs, IRF5 
and LMCD1 that may play an important role in EMT 
induction. Our data suggest that LMCD1 acts as an 
enhancer of TGF- beta- dependent EMT processes, while 
IRF5 functions as a negative regulator of EMT. LMCD1 
is a member of the LIM protein family containing two 
C- terminal LIM domains, a central PET domain, and an 
N- terminal cysteine- rich region [31]. LMCD1 was previ-
ously described as a transcriptional co- repressor of GATA6, 
whereas its role in cytoskeletal compartments remains to 
be elucidated [32]. LMCD1 E135K somatic mutation was 
associated with cell migration and tumor metastasis in 
hepatocellular carcinoma (HCC); its up- regulation was 
also positively correlated with infiltrative tumor growth 
patterns in HCC patients, implying its possible involve-
ment in tumor cell invasiveness [33]. Our data directly 
reveal for the first time to our knowledge that upregulated 
LMCD1 may intermediate EMT progression and contribute 
to tumor cell invasiveness and metastasis.
Conversely, IRF5 has been reported as a tumor repres-
sor in breast cancer and negatively regulates CD24 expres-
sion, but similarly, no association with date has been 
shown between IRF5 and EMT to the best of our knowl-
edge [15, 34]. We also observed that IRF5 knockdown 
in preEMT H358 cells increased CD24+ cell subpopulation 
(from 0.6% to 4.1%, Fig. 4D, upper panel). Interestingly, 
we found that the IRF5- mediated CD24 repression is 
particularly significant and important for cells under expo-
sure of EMT- inducing cytokines such as TGF- beta. 
Knockdown of IRF5 led to a much more dramatic increase 
in CD24+ expression in the cells exposed to TGF- beta/
OSM, as compared to untreated cells. Knockdown of IRF5 
also significantly increased CD44+ expression in postEMT 
cells, suggesting its critical repressive role in CD44 and 
CD24 regulation during EMT.
Finally, but no less interestingly, we found that SMAD7, 
a reported EMT repressor that antagonizes TGF- beta sign-
aling [35], was actually significantly upregulated in 
postEMT cells in our EMT model in both H358 and 
MCF10a cell lines (Table 1). Heikkinen et al. reported 
that hypoxic conditions could convert SMAD7 function 
from an inhibitor into a promoter of cell invasion in 
cancer, which was supported by evidence that increased 
SMAD7 expression in human cancer correlated with 
hypoxic gene expression. Further studies are needed to 
better understand how SMAD7 functions during EMT 
and metastasis [36].
Taken together, our data help shed new light into the 
transcriptional landscape of EMT and its regulation. Future 
studies will need to continue to address how these numer-
ous EMT- related networks, and regulating genes such as 
TFs, are dynamically orchestrated during EMT. This could 
eventually result in development of new prognostic tools 
and biomarkers, and provide promising targets for the 
development of novel EMT- based treatments for cancers.
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